1021919-64-1

Basic information

• Product Name: 1H-IMidazo[4,5-b]pyridine-1-carboxylic acid, 6-broMo-2,3-dihydro-2-oxo-, ethyl ester
• Synonyms: 1H-IMidazo[4,5-b]pyridine-1-carboxylic acid, 6-broMo-2,3-dihydro-2-oxo-, ethyl ester;Ethyl 6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-carboxylate
• CAS NO: 1021919-64-1
• Molecular Formula: C₉H₈BrN₃O₃
• Molecular Weight: 286.08212
• Mol File: 1021919-64-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-IMidazo[4,5-b]pyridine-1-carboxylic acid, 6-broMo-2,3-dihydro-2-oxo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-IMidazo[4,5-b]pyridine-1-carboxylic acid, 6-broMo-2,3-dihydro-2-oxo-, ethyl ester(1021919-64-1)
• EPA Substance Registry System: 1H-IMidazo[4,5-b]pyridine-1-carboxylic acid, 6-broMo-2,3-dihydro-2-oxo-, ethyl ester(1021919-64-1)

Safety Data

• Hazardous Substances Data: 1021919-64-1(Hazardous Substances Data)

Usage

Description

1H-Imidazo[4,5-b]pyridine-1-carboxylic acid, 6-Bromo-2,3-dihydro-2-oxo-, ethyl ester is a chemical compound that belongs to the class of ethyl esters. It is derived from 1H-Imidazo[4,5-b]pyridine-1-carboxylic acid and features a 6-Bromo and 2,3-dihydro-2-oxo functional groups. 1H-IMidazo[4,5-b]pyridine-1-carboxylic acid, 6-broMo-2,3-dihydro-2-oxo-, ethyl ester is known for its potential therapeutic benefits, particularly in the treatment of cancer and inflammatory diseases. The presence of the ethyl ester group enhances its bioavailability, making it a promising candidate for pharmaceutical applications.

Uses

Used in Pharmaceutical Industry:
1H-Imidazo[4,5-b]pyridine-1-carboxylic acid, 6-Bromo-2,3-dihydro-2-oxo-, ethyl ester is used as a therapeutic agent for treating cancer and inflammatory diseases. Its unique structure, including the 6-Bromo and 2,3-dihydro-2-oxo groups, may impart specific pharmacological properties that contribute to its effectiveness in addressing these conditions.
Additionally, the compound's enhanced bioavailability due to the presence of the ethyl ester group makes it easier to administer as a medication, increasing its potential for use in drug development and research. 1H-IMidazo[4,5-b]pyridine-1-carboxylic acid, 6-broMo-2,3-dihydro-2-oxo-, ethyl ester may also be valuable for further exploration in the pharmaceutical industry to develop new medications for a variety of health conditions.

Upstream product

• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 7325-39-5 ethyl pyridine-2-yl carbonate 
• 530-62-1 1,1'-carbonyldiimidazole 
• 148038-83-9 6-bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 

Downstream Products

• 1229583-25-8 1-(1H-indol-5-yl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one 
• 1229583-26-9 1-(cyclopropylmethyl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one 

Relevant articles and documents

Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders

Selective inhibitors of the GluN2B subunit of N-methyl-d-aspartate receptors in the ionotropic glutamate receptor superfamily have been targeted for the treatment of mood disorders. We sought to identify structurally novel, brain penetrant, GluN2B-selective inhibitors suitable for evaluation in a clinical setting in patients with major depressive disorder. We identified a new class of negative allosteric modulators of GluN2B that contain a 1,3-dihydro-imidazo[4,5-b]pyridin-2-one core. This series of compounds had poor solubility properties and poor permeability, which was addressed utilizing two approaches. First, a series of structural modifications was conducted which included replacing hydrogen bond donor groups. Second, enabling formulation development was undertaken in which a stable nanosuspension was identified for lead compound 12. Compound 12 was found to have robust target engagement in rat with an ED70 of 1.4 mg/kg. The nanosuspension enabled sufficient margins in preclinical toleration studies to nominate 12 for progression into advanced good laboratory practice studies.

MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES

Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.

MLK INHIBITORS AND METHODS OF USE

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.